Loading
A phase 3 trial of Elinzanetant (BAY3427080) in HR-positive / HER2-negative breast cancer, run by Bayer, active and no longer recruiting.
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer is a phase 3 interventional study registered as NCT05587296 by Bayer, with 474 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2024-01-29. Interventions recorded: Elinzanetant (BAY3427080) and Placebo. Results have been posted on the registry.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bayer and the tag pipeline.
Shares Bayer and the tag pipeline.
Shares Bayer and the tag pipeline.
Shares Bayer and the tag pipeline.
Shares Bayer and the tag pipeline.
Shares Bayer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/